JP2019509280A5 - - Google Patents

Download PDF

Info

Publication number
JP2019509280A5
JP2019509280A5 JP2018544904A JP2018544904A JP2019509280A5 JP 2019509280 A5 JP2019509280 A5 JP 2019509280A5 JP 2018544904 A JP2018544904 A JP 2018544904A JP 2018544904 A JP2018544904 A JP 2018544904A JP 2019509280 A5 JP2019509280 A5 JP 2019509280A5
Authority
JP
Japan
Prior art keywords
compound
independently
hydrogen
alkyl
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018544904A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509280A (ja
JP7161404B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/051054 external-priority patent/WO2017145097A2/en
Publication of JP2019509280A publication Critical patent/JP2019509280A/ja
Publication of JP2019509280A5 publication Critical patent/JP2019509280A5/ja
Application granted granted Critical
Publication of JP7161404B2 publication Critical patent/JP7161404B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018544904A 2016-02-26 2017-02-24 アミノ酸及びペプチド接合体及び接合方法 Active JP7161404B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016900701A AU2016900701A0 (en) 2016-02-26 Amino acid and peptide conjugates and conjugation process
AU2016900701 2016-02-26
PCT/IB2017/051054 WO2017145097A2 (en) 2016-02-26 2017-02-24 Amino acid and peptide conjugates and conjugation process

Publications (3)

Publication Number Publication Date
JP2019509280A JP2019509280A (ja) 2019-04-04
JP2019509280A5 true JP2019509280A5 (cg-RX-API-DMAC7.html) 2020-04-09
JP7161404B2 JP7161404B2 (ja) 2022-10-26

Family

ID=59685928

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018544904A Active JP7161404B2 (ja) 2016-02-26 2017-02-24 アミノ酸及びペプチド接合体及び接合方法

Country Status (13)

Country Link
US (1) US11464853B2 (cg-RX-API-DMAC7.html)
EP (1) EP3419962A4 (cg-RX-API-DMAC7.html)
JP (1) JP7161404B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180128915A (cg-RX-API-DMAC7.html)
CN (1) CN108884020A (cg-RX-API-DMAC7.html)
AU (2) AU2017223267B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018017174A2 (cg-RX-API-DMAC7.html)
CA (1) CA3014515A1 (cg-RX-API-DMAC7.html)
EA (1) EA201891639A1 (cg-RX-API-DMAC7.html)
IL (1) IL261112A (cg-RX-API-DMAC7.html)
SG (1) SG11201807036QA (cg-RX-API-DMAC7.html)
TW (1) TW201735952A (cg-RX-API-DMAC7.html)
WO (1) WO2017145097A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10576144B2 (en) 2013-06-28 2020-03-03 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
JP2018505152A (ja) 2014-12-23 2018-02-22 アン ブリンブル マーガレット アミノ酸複合体及びペプチド複合体ならびにそれらの使用
US11464853B2 (en) 2016-02-26 2022-10-11 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
TW201925240A (zh) * 2017-08-30 2019-07-01 紐西蘭商奧克蘭聯合服務公司 肽共軛物、共軛過程及其用途
WO2019119067A1 (en) 2017-12-21 2019-06-27 Ena Therapeutics Pty Ltd Optimised compounds
CN113260377B (zh) * 2018-12-20 2025-08-22 维罗米蒂克斯股份公司 脂肽构建块和合成病毒样颗粒
KR20220050873A (ko) * 2019-06-26 2022-04-25 악셀리아 온콜로지 피티와이 리미티드 신규한 분자
EP3838967A1 (en) * 2019-12-16 2021-06-23 Spago Nanomedical AB Immobilization of phenolic compounds
US20230278954A1 (en) * 2020-06-26 2023-09-07 Ena Respiratory Pty Ltd Branched lipid compouds

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4939240A (en) 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US6024964A (en) 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US6074650A (en) 1985-06-24 2000-06-13 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
DE3813821A1 (de) 1988-04-22 1989-11-02 Hoechst Ag Synthetische vakzine gegen die maul- und klauenseuche und verfahren zu deren herstellung
US4743543A (en) 1985-09-09 1988-05-10 Coulter Corporation Method for enhancing and/or accelerating immunoassay detection of human carcinoma tumor associated antigen in a pathology sample
US4921790A (en) 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
US4963484A (en) 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US5053489A (en) 1988-01-29 1991-10-01 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US4914021A (en) 1988-03-04 1990-04-03 New England Deaconess Hospital Corporation Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
US4921789A (en) 1988-04-20 1990-05-01 New England Deaconess Hospital Corporation Marker for colorectal carcinoma and methods of detecting the same
JPH02172946A (ja) 1988-12-26 1990-07-04 Shinetsu Sakusan Vinyl Kk カルボン酸アルケニルエステルの製造方法
US5110911A (en) 1989-11-02 1992-05-05 Biomira, Inc. Human tumor-associated thomsen-friedenreich antigen
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
CA2117477C (en) 1992-12-11 2001-06-12 Peter S. Mezes Multivalent single chain antibodies
ATE244888T1 (de) 1993-02-05 2003-07-15 Epigen Inc Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy
US6310180B1 (en) 1993-06-21 2001-10-30 Vanderbilt University Method for synthesis of proteins
DE4331011A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit C-Verzweigung für Therapie und Diagnostik
AUPM446594A0 (en) 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
JPH08248579A (ja) 1995-03-14 1996-09-27 Mitsubishi Paper Mills Ltd ハロゲン化銀写真感光材料及びその処理方法
US5994294A (en) 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
US6251603B1 (en) 1996-10-03 2001-06-26 Ludwig Institute For Cancer Research Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
AU9572098A (en) 1997-10-08 1999-04-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Novel human cancer antigen ny eso-1/cag-3 and gene encoding same
US6602505B2 (en) 1998-04-30 2003-08-05 University Of Southern California Viral chimeras comprised of CAEV and HIV-1 genetic elements
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
ES2223464T3 (es) 1999-02-01 2005-03-01 Eisai Co., Ltd. Compuestos adyuvantes inmunologicos.
EP1230261B1 (en) 1999-11-15 2008-06-25 Ludwig Institute For Cancer Research Ny-eso-1 nonapeptide derivatives, and uses thereof
WO2001055393A2 (en) 2000-01-28 2001-08-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
AU2001273639A1 (en) 2000-06-26 2002-01-08 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
US6506875B1 (en) 2000-09-26 2003-01-14 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-C molecules and uses thereof
GB0030067D0 (en) 2000-12-11 2001-01-24 Univ Bristol Therapeutic agent
EP1229043A1 (en) 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US7887833B2 (en) 2001-12-04 2011-02-15 Ben-Gurion University Of The Negev Research And Development Authority Amphiphilic compounds and vesicles liposomes for organ-specified drug targeting
JP4643255B2 (ja) 2002-06-10 2011-03-02 バクシネックス インコーポレーティッド 乳癌および膀胱癌において差次的に発現される遺伝子ならびにコードされるポリペプチド
GB0214528D0 (en) 2002-06-24 2002-08-07 Univ Aberdeen Materials and methods for induction of immune tolerance
JP4619121B2 (ja) 2002-08-12 2011-01-26 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ Tヘルパーエピトープおよび細胞傷害性tリンパ球(ctl)エピトープを含む新規な免疫原性リポペプチド
WO2004014956A1 (en) 2002-08-12 2004-02-19 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes
TW200416043A (en) 2002-11-07 2004-09-01 Queensland Inst Med Res Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
US20080139464A1 (en) 2003-05-30 2008-06-12 Ludwig Institute Of Cancer Research Isolated Ny-Eso-1 Peptides Which Bind To Hla Class II Molecules And Uses Thereof
US20070197541A1 (en) 2003-07-29 2007-08-23 Oyelere Adegboyega K Biaryl heterocyclic amines,amides, and sulfur-containing compounds and methods of making and using the same
EP1666056A1 (en) 2004-12-06 2006-06-07 Bestewil Holding B.V. Cancer vaccine vesicles
FR2881746B1 (fr) 2005-02-07 2007-04-13 Centre Nat Rech Scient Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
DK1850832T3 (en) 2005-02-07 2015-04-13 Lipotek Pty Ltd adjuvanting
CN101151280A (zh) 2005-02-08 2008-03-26 昆士兰医学研究学院委员会 免疫原性分子
GB0507003D0 (en) 2005-04-06 2005-05-11 Molmed Spa Therapeutic
AU2006247471A1 (en) 2005-05-12 2006-11-23 Tapestry Pharmaceuticals, Inc. Molecular constructs suitable for targeted conjugates
JP2009511559A (ja) 2005-10-12 2009-03-19 バイオリポックス エービー 炎症の治療に有用なベンゾオキサゾール類
JP4824389B2 (ja) 2005-10-28 2011-11-30 株式会社医学生物学研究所 エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性t細胞エピトープペプチド及びその用途
EP1963358A4 (en) 2005-12-06 2009-03-25 Univ Australian TREATMENT OF DISEASES ASSOCIATED WITH THE EPSTEIN-BARR-VIRUS
WO2007078879A2 (en) 2005-12-21 2007-07-12 Vaxinnate Corporation Lipopeptide compositions and methods of use thereof
WO2010002478A2 (en) * 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
CA2674269C (en) * 2006-01-03 2018-06-12 University Of Georgia Research Foundation, Inc. Three component glycolipopeptides
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
US20090123488A1 (en) 2006-08-14 2009-05-14 Thymon, Llc Compositions and methods for the treatment and prophylaxis of Alzheimer's disease
CA2674458A1 (en) 2007-01-15 2008-07-24 Glaxosmithkline Biologicals S.A. Fusion protein
US8309096B2 (en) 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
EP3533461A3 (en) 2007-03-26 2019-12-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Prame derived peptides and immunogenic compositions comprising these
WO2008151197A2 (en) 2007-06-04 2008-12-11 The Regents Of The University Of California Tumor-derived endogenous toll-like receptor 4 ligands
US20100266623A1 (en) 2008-07-07 2010-10-21 The University Of Melbourne Synthetic, self adjuvanting vaccines
US20110262473A1 (en) 2008-07-07 2011-10-27 The University Of Melbourne Synthetic vaccine component
EP2334332A4 (en) * 2008-09-05 2013-01-09 Id Biomedical Corp Quebec NEW COMPOSITIONS AND NEW ADJUVANTS
US8436015B2 (en) 2008-09-15 2013-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2012523379A (ja) * 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
GB0917090D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
EP2504315A1 (en) 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2011063272A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2011109237A2 (en) 2010-03-02 2011-09-09 Emory University Uses of noscapine and derivatives in subjects diagnosed with fap
EP2550298B1 (en) 2010-03-23 2015-07-15 The Regents of The University of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
US20130029358A1 (en) 2010-04-01 2013-01-31 Ludwig Institute For Cancer Research Ltd. Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
WO2011156686A2 (en) 2010-06-11 2011-12-15 The Regents Of The University Of Colorado, A Body Corporate Method for synthesizing a cyclic multivalent peptide using a thiol-mediated reaction
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
ES2655535T3 (es) 2010-08-25 2018-02-20 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Una vacuna contra el virus de Epstein-Barr
AU2011295845B2 (en) 2010-09-01 2016-09-22 Baylor College Of Medicine EBV-specific cytotoxic T-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (NPC)
AU2011303430B2 (en) 2010-09-14 2014-09-11 Council Of Scientific And Industrial Research A synthetic immunogen useful for generating long lasting immunity and protection against pathogens
ME02810B (me) 2010-09-20 2018-01-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t ćelijski receptori i t ćelijski epitopi
CN103189072B (zh) 2010-09-22 2018-02-09 因纳瓦克私人有限公司 免疫刺激方法
WO2012069188A1 (en) 2010-11-24 2012-05-31 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V Continuous flow processes for photoconjugation of high-molecular chemical entities
US9187534B2 (en) 2011-03-11 2015-11-17 Universite De Geneve Multi-epitopic vaccine
EP2686020B1 (en) 2011-03-17 2017-02-22 The University of Birmingham Re-directed immunotherapy
WO2012158122A1 (en) 2011-05-13 2012-11-22 Nanyang Technological University Method for modification of organic molecules
US20120328660A1 (en) 2011-06-03 2012-12-27 Tsuji Takemasa Immunogenic compositions useful in provoking an integrated response to tumor antigens
CN102839186A (zh) 2011-06-21 2012-12-26 上海生物制品研究所有限责任公司 表达ny-eso-1重组耻垢分枝杆菌的制备及应用
GB201114051D0 (en) 2011-08-15 2011-09-28 Domainex Ltd Compounds and their uses
WO2013036543A2 (en) 2011-09-10 2013-03-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Molecular imaging of cancer cells in vivo
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
IN2014CN02581A (cg-RX-API-DMAC7.html) 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
US9056141B2 (en) 2012-05-31 2015-06-16 Synchem, Inc. Thiol-ene click chemistry for drug conjugates
US9861702B2 (en) 2012-10-22 2018-01-09 Wisconsin Alumni Research Foundation Lipid-conjugated rhamnose for immune system recruitment and oncotherapy
CA2893918C (en) 2012-12-06 2020-11-24 Callaghan Innovation Research Limited Conjugate compounds
US10576144B2 (en) 2013-06-28 2020-03-03 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
JP2018505152A (ja) 2014-12-23 2018-02-22 アン ブリンブル マーガレット アミノ酸複合体及びペプチド複合体ならびにそれらの使用
US11464853B2 (en) 2016-02-26 2022-10-11 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process

Similar Documents

Publication Publication Date Title
JP2019509280A5 (cg-RX-API-DMAC7.html)
JP2020532534A5 (cg-RX-API-DMAC7.html)
ES2732999T3 (es) Derivados de oxoadenina lipidada
Levi et al. Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection
JP2016523891A5 (cg-RX-API-DMAC7.html)
JP2016505586A5 (cg-RX-API-DMAC7.html)
JP2015512946A5 (cg-RX-API-DMAC7.html)
JP2019043957A5 (cg-RX-API-DMAC7.html)
JP2018504412A5 (cg-RX-API-DMAC7.html)
RU2015142996A (ru) Пептидная вакцина для предупреждения и иммунотерапии деменции альцгеймеровского типа
JP2019514426A5 (cg-RX-API-DMAC7.html)
JP2014503525A5 (cg-RX-API-DMAC7.html)
JP2016540050A5 (cg-RX-API-DMAC7.html)
RU2015146614A (ru) Конъюгированная вакцина на основе пептида антигена wt1
JP2014515406A5 (cg-RX-API-DMAC7.html)
JP2012501959A5 (cg-RX-API-DMAC7.html)
JP2015521206A5 (cg-RX-API-DMAC7.html)
FI3518982T3 (fi) Säädellysti vapautuvia PTH-yhdisteitä
JP2018531578A5 (cg-RX-API-DMAC7.html)
CN104619718A (zh) 源自病毒蛋白的肽用作免疫原和配药成分
JP2020015742A5 (cg-RX-API-DMAC7.html)
JP2014502961A5 (cg-RX-API-DMAC7.html)
JP2015517484A5 (cg-RX-API-DMAC7.html)
JP2019534242A5 (cg-RX-API-DMAC7.html)
JP2016502503A5 (cg-RX-API-DMAC7.html)